Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Aug 7, 2024
Product Development

Jim Wilson’s move to industry is anchored in global vision for ultrarare diseases

Gene therapy pioneer tells BioCentury his plans for his newcos GemmaBio and Franklin Biolabs
BioCentury | Apr 30, 2022
Distillery Therapeutics

Suppressor tRNA gene therapy for nonsense mutations

BioCentury | Nov 19, 2021
Finance

Nov. 18 Quick Takes: RA’s Avilar raises $60M seed for protein degradation tech

Sanofi invests in Owkin, plus Treadwell, Protego, BAKX, Fountain, Takeda-Denali
BioCentury | Mar 15, 2017
Distillery Therapeutics

Cancer

BioCentury | Dec 22, 2014
Finance

Flexible funding for CRT

CRT Pioneer Fund's plans for its latest cash influx
BioCentury | Feb 3, 2014
Company News

Servier, Institut Curie deal

BioCentury | Jan 16, 2014
Distillery Therapeutics

Indication: Cancer

BioCentury | Aug 5, 2013
Company News

Nerviano, Servier deal

Items per page:
1 - 10 of 15